EUSA Pharma Announces Appointment of Carsten Thiel as New Chief Executive Officer
EUSA Pharma UK Ltd (“EUSA”), a global biopharmaceutical company focused on oncology and rare disease, today announced the appointment of Carsten Thiel as Chief Executive Officer (CEO) with immediate effect, succeeding Lee Morley, who is stepping down after 6 years as CEO. Dr Thiel has led EUSA’s Europe Region and Global Marketing over the past two years.
Bryan Morton, CBE, EUSA Pharma’s Executive Chairman, said, “Lee has been pivotal in EUSA’s success since it was founded in 2015 and we thank him for the instrumental role he has played over the years. As EUSA continues to grow, we are delighted to appoint Carsten to the CEO role. We have known Carsten for several years and have been continually impressed by his ability to build and lead strong teams, and to execute well on ambitious growth plans. I am personally excited to work with Carsten in his new role to further establish EUSA as a leading global biopharmaceutical company.”
Prior to joining EUSA Pharma in 2019, Dr Thiel gained 27 years of experience in a variety of international roles in the pharmaceutical industry. Previously he served as Chief Commercial Officer at Alexion Pharmaceuticals Inc and in advance of this he worked for 14 years at Amgen, where he held multiple roles of increasing commercial responsibility, including the Head of Europe. He spent his first 10 years in the pharmaceutical industry at Hoffmann La-Roche in various roles. Dr Thiel holds a PhD in Molecular Biology and Biochemistry from the Max Planck Institute in Germany.
Carsten Thiel, EUSA Pharma’s Chief Executive Officer, said, “I am incredibly honoured to become EUSA Pharma’s next CEO. EUSA has made great progress, building an impressive oncology and rare disease business globally in just a few years. We have a strong culture, strong team and a true patient focus. We are in an ideal position to take greater strides forward and I look forward to working with our team and our Board as we advance EUSA’s mission to help patients to live and embrace life.”
About EUSA Pharma
Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. The company has extensive commercial operations in the United States and Europe, alongside a direct presence in select other markets across the globe. EUSA Pharma is led by an experienced management team with a strong record of building successful pharmaceutical companies, and is supported by significant funding raised from leading life science investor EW Healthcare Partners. For more information please visit www.eusapharma.com.